{
    "id": 7045,
    "fullName": "VHL loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "VHL loss indicates loss of the VHL gene, mRNA and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7428,
        "geneSymbol": "VHL",
        "terms": [
            "VHL",
            "HRCA1",
            "pVHL",
            "RCA1",
            "VHL1"
        ]
    },
    "variant": "loss",
    "createDate": "06/04/2015",
    "updateDate": "10/11/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition in culture when treated with CB-839 (PMID: 28346230).",
            "molecularProfile": {
                "id": 6901,
                "profileName": "VHL loss"
            },
            "therapy": {
                "id": 1667,
                "therapyName": "CB-839",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8915,
                    "pubMedId": 28346230,
                    "title": "Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28346230"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2272,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246).",
            "molecularProfile": {
                "id": 6901,
                "profileName": "VHL loss"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2902,
                    "pubMedId": 22931246,
                    "title": "Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22931246"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230).",
            "molecularProfile": {
                "id": 6901,
                "profileName": "VHL loss"
            },
            "therapy": {
                "id": 5194,
                "therapyName": "BPTES",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8915,
                    "pubMedId": 28346230,
                    "title": "Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28346230"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10901,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CB-839 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating greater reduction in tumor volume compared to either agent alone in renal carcinoma cell xenograft models deficient for VHL (PMID: 28346230).",
            "molecularProfile": {
                "id": 6901,
                "profileName": "VHL loss"
            },
            "therapy": {
                "id": 5675,
                "therapyName": "CB-839 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8915,
                    "pubMedId": 28346230,
                    "title": "Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28346230"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BPTES and Lynparza (olaparib) resulted in a synergistic effect, demonstrating growth inhbition of VHL-deficient renal cell carcinoma cells in culture (PMID: 28346230).",
            "molecularProfile": {
                "id": 6901,
                "profileName": "VHL loss"
            },
            "therapy": {
                "id": 5677,
                "therapyName": "BPTES + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8915,
                    "pubMedId": 28346230,
                    "title": "Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28346230"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2273,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124).",
            "molecularProfile": {
                "id": 6901,
                "profileName": "VHL loss"
            },
            "therapy": {
                "id": 2790,
                "therapyName": "ELR510444",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2953,
                    "pubMedId": 22295124,
                    "title": "ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22295124"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3157,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 11820,
                "profileName": "PTEN loss VHL loss"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 4451,
                "name": "renal carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6901,
            "profileName": "VHL loss",
            "profileTreatmentApproaches": [
                {
                    "id": 5266,
                    "name": "VEGFR2 Inhibitor",
                    "profileName": "VHL loss"
                },
                {
                    "id": 5265,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "VHL loss"
                },
                {
                    "id": 5264,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "VHL loss"
                }
            ]
        },
        {
            "id": 11820,
            "profileName": "PTEN loss VHL loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}